The Pharmaceutical Market: Venezuela

The Pharmaceutical Market: Venezuela

OVERVIEW OF THE PHARMACEUTICAL MARKET IN VENEZUELA We expect the Venezuelan government to continue its foreign currency and import control policies in Q412 and the local market will endure further government restrictions on pharmaceutical and healthcare industry. Multinationals will have the potential revenue-generation opportunities from Venezuela's increasing reliance on imported products to meet local demand, as the election outcome will not fix the production capacity issues in the domestic industry. Headline Expenditure Projections Pharmaceuticals: VEB33.26bn (US$5.46bn) in 2011 to VEB40.77bn (US$6.00bn) in 2012; +22.6% in local currency terms and +10.0% in US dollar terms. Forecasts down due to new industrial information. Healthcare: VEB66.69bn (US$10.94bn) in 2011 to VEB83.29bn (US$12.26bn) in 2012; +24.9% in local currency terms and +12.0% in US dollar terms. Forecasts up due to new macro data. Medical devices: VEB9.62bn (US$1.58bn) in 2011 to VEB11.54bn (US$1.70bn) in 2012; +20.0% in local currency terms and 7.6% in US dollar terms. Forecasts down due to new macroeconomic data. Competitive Landscape The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. table Of Contents

bmi Industry View 7

swot 9

political 11

economic 12

business Environment 13

industry Forecast 14

pharmaceutical Market Forecast 14 table: Pharmaceutical Sales, 2009-2017 15

healthcare Market Forecast 16 table: Overall Healthcare Expenditure, 2009-2017 17 table: Government Healthcare Expenditure, 2009-2017 17 table: Private Healthcare Expenditure, 2009-2017 17

economic Analysis 18 table: Venezuela - Gdp By Expenditure, Real Growth % 22

prescription Drug Market Forecast 23 table: Prescription Drug Sales, 2009-2017 24

patented Drug Market Forecast 24...